Aspirin’s Lung-Protective Effects May Decrease Ventilation, ICU Admission and Death in COVID-19 Patients
By HospiMedica International staff writers Posted on 23 Aug 2021 |
Illustration
Researchers have found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients.
The study of the lung protective effects of aspirin by researchers from the George Washington University (Washington, D.C., USA) involved over 400 COVID-19 patients admitted from March to July 2020 to hospitals around the US. After adjusting for demographics and comorbidities, aspirin use was associated with a decreased risk of mechanical ventilation (44% reduction), ICU admission (43% reduction), and in-hospital mortality (47% reduction). There were no differences in major bleeding or overt thrombosis between aspirin users and non-aspirin users.
Preliminary findings were first published as a preprint in fall 2020. Since then, other studies have confirmed the impact aspirin can have on both preventing infection and reducing risk for severe COVID-19 and death. The researchers hope that this study leads to more research on whether a causal relationship exists between aspirin use and reduced lung injury in COVID-19 patients.
“As we learned about the connection between blood clots and COVID-19, we knew that aspirin – used to prevent stroke and heart attack – could be important for COVID-19 patients,” said Jonathan Chow, MD, assistant professor of anesthesiology and critical care medicine and director of the Critical Care Anesthesiology Fellowship at the GW School of Medicine and Health Sciences. “Our research found an association between low dose aspirin and decreased severity of COVID-19 and death.”
“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” added Chow. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”
Related Links:
George Washington University
The study of the lung protective effects of aspirin by researchers from the George Washington University (Washington, D.C., USA) involved over 400 COVID-19 patients admitted from March to July 2020 to hospitals around the US. After adjusting for demographics and comorbidities, aspirin use was associated with a decreased risk of mechanical ventilation (44% reduction), ICU admission (43% reduction), and in-hospital mortality (47% reduction). There were no differences in major bleeding or overt thrombosis between aspirin users and non-aspirin users.
Preliminary findings were first published as a preprint in fall 2020. Since then, other studies have confirmed the impact aspirin can have on both preventing infection and reducing risk for severe COVID-19 and death. The researchers hope that this study leads to more research on whether a causal relationship exists between aspirin use and reduced lung injury in COVID-19 patients.
“As we learned about the connection between blood clots and COVID-19, we knew that aspirin – used to prevent stroke and heart attack – could be important for COVID-19 patients,” said Jonathan Chow, MD, assistant professor of anesthesiology and critical care medicine and director of the Critical Care Anesthesiology Fellowship at the GW School of Medicine and Health Sciences. “Our research found an association between low dose aspirin and decreased severity of COVID-19 and death.”
“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” added Chow. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”
Related Links:
George Washington University
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans